Can-Fite Pharmaceuticals has received a patent allowance in Canada for the use of Namodenoson as a therapy for obesity. The drug’s oral safety profile and its effects on metabolism support its potential application in managing obesity.
Namodenoson is being developed to address the increasing demand for effective obesity treatments. The patent protection in Canada strengthens Can-Fite’s position in the expanding market for metabolic and weight management therapies.
**Why this matters**
Obesity is a growing global health concern with significant medical and economic impacts. Developing safe and effective treatments like Namodenoson could provide new options for patients. Securing patent rights in key markets is crucial for advancing clinical development and commercial opportunities.
Source: NewsData